We are live on ! Find out more
APTO

Aptose Biosciences

Delisted

APTO was delisted on the 1st of April, 2025.

64 hedge funds and large institutions have $86.5M invested in Aptose Biosciences in 2021 Q3 according to their latest regulatory filings, with 11 funds opening new positions, 23 increasing their positions, 20 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

15% more repeat investments, than reductions

Existing positions increased: 23 | Existing positions reduced: 20

10% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 10

2% more funds holding

Funds holding: 63 → 64 (+1)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

8.58% less ownership

Funds ownership: 53.1% → 44.52% (-8.6%)

32% less call options, than puts

Call options by funds: $251K | Put options by funds: $370K

62% less capital inflows, than outflows

Capital inflows: $14.7M | Capital outflows: $38.7M

Holders
64
Holders Change
+1
Holders Change %
+1.59%
% of All Funds
1.12%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
11
Increased
23
Reduced
20
Closed
10
Calls
$251​K
Puts
$370​K
Net Calls
-⁠$119​K
Net Calls Change
-⁠$50​K

APTO Hedge Fund Activity: Q3 2021 in Review

64 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Aptose Biosciences (APTO) for Q3 2021, worth a combined $86.5M — down 45% from $157M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new APTO positions and 10 closed out — a net gain of 1 holder — while 23 added to existing stakes and 20 trimmed.

The largest buyer was 683 Capital Management, adding an estimated $2.56M. The largest seller was OrbiMed, cutting an estimated $15.1M.

  • 64 institutional investors held Aptose Biosciences (APTO) as of Q3 2021, up from 63 in Q2 2021.
  • Funds reported $86.5M of Aptose Biosciences stock for Q3 2021, down 45% quarter-over-quarter.
  • 11 funds opened new Aptose Biosciences positions in Q3 2021 and 10 closed out, a net change of +1 holder.
  • The largest Aptose Biosciences buyer in Q3 2021 was 683 Capital Management, an estimated $2.56M added.
  • The largest Aptose Biosciences seller in Q3 2021 was OrbiMed, an estimated $15.1M sold.

Based on aggregated 13F filings for Q3 2021.